Immediate oral amiodarone re-challenge following the development of parenteral-induced acute liver toxicity  

作　　者：Joseph Off enbacher Farnam Kazi Niel Chen Mohamed Mohamed Jasmine Chacko Nils Guttenplan Vincent Nguyen 

机构地区：[1]Department of Emergency Medicine,Jacobi and Montefi ore Hospitals,Albert Einstein College of Medicine,Bronx 10461,USA [2]Department of Pharmacy,Montefi ore Medical Center,Bronx 10461,USA [3]Department of Medicine(Division of Cardiology),Montefi ore Hospitals,Albert Einstein College of Medicine,Bronx 10461,USA [4]Department of Emergency Medicine,Jacobi Hospital,Albert Einstein College of Medicine,Bronx 10461,USA

出　　处：《World Journal of Emergency Medicine》2021年第4期321-323,共3页世界急诊医学杂志（英文）

摘　　要：Dear editor,Amiodarone is a class Ⅲ antiarrhythmic medication commonly used in the emergency department (ED) and other critical care settings to treat several types of arrhythmias while also serving as a fixture of the Advanced Cardiac Life Support algorithm.[1] Its mechanism of action primarily involves blocking potassium channel currents during myocyte repolarization with additional effects on betaadrenergic receptors and both sodium and calcium channel blockade.[2] One of amiodarone’s less known complications is the development of acute hepatotoxicity with intravenous(IV) administration.[3] While discontinuation has been recommended, there is limited literature to help guide management when clinical factors warrant its continuation.

关 键 词：CONTINUATION editor POTASSIUM 

分 类 号：R969[医药卫生—药理学]